Ads
related to: advanced lung cancer prognosis- Dosing & Administration
See Important HCP Dosing Guidelines
For FDA Approved Treatment.
- Treatment Overview
View Treatment Summary & Overview
At The Official ES-SCLC Website.
- Clinical Study Results
Review Data From Clinical Trials
And Find Efficacy & Safety Info.
- About SCLC
Learn More About A Treatment Option
Available For Your Patients.
- Connect With A Rep
Get Personalized Support That
You And Your Patients Can Count On.
- Download HCP Resources
Find Important Physician Guides
For Your Practice And Patients.
- Dosing & Administration
Search results
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 17 hours agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 hours agoInnovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant ...
...2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid...
Char-Koosta News· 1 day agoMore updated data from the Phase 1 study including in non-small cell lung cancer will be presented...
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative...
WROC Rochester· 6 days agoData from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoThe results showed a 12-month overall survival (“OS”) rate of 69%, a median overall survival (“mOS”) of 17.5 months...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Forrest City Times-Herald· 2 days agoResults from the new analysis show the RYBREVANT® combination consistently and significantly improved progression-free survival (PFS) compared to osimertinib in patients with ...
ASCO: Early Purple data gain ground in metastatic pancreatic cancer
FierceBiotech· 2 days agoPurple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true...
No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
MedPage Today· 1 day agoResults are 'disappointing as we need better therapies in the refractory space,' expert says
Why Are Younger People Getting Cancer?
US News Health· 4 days agoAt age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. Cancer screenings are happening at younger ...
Ads
related to: advanced lung cancer prognosis